Skip to content
EMA to Review New Safety Data on Alzheimer’s Drug Leqembi
2025-02-01
The European Medicines Agency (EMA) announced it will review new safety data on the Alzheimer’s disease drug Leqembi (lecanemab). This follows a prior decision to recommend its use in the European Union. Lecanemab is indicated for treating mild cognitive impairment and early Alzheimer’s disease. It is intended for patients withContinue Reading
